In another study, the combined treatment of BRAF/MEK inhibitors vemurafenib and trametinib in melanoma xenografts showed no significant changes in lactate-to-pyruvate ratios before treatment and after 24 h of combination treatment. This evidence concerns the gene BRAF and melanoma.